The bad news is all the noobs taking over the message board, telling us #$%$ we've known for 2 years.
I for one would be open to an objective assessment, which FurStain's article most definitely was not.
What he wrote was so poorly thought out and constructed, it's obviously just a typical hit piece. This guy belongs in jail for conspiracy to manipulate stocks.
Two billion dollar drugs on the market and a pipeline takes the stock over 200. Quite possible in 4 years. People wanting a buyout at 30 are fools.
Then what are your targets should the following milestones be reached over the next few years?
1. FDA approval
2. Aldox on the market
3. Aldox 1 billion in sales
4. Algem looking promising and a third conjugate in the pipeline
5. Tender from a big pharma
June 20, just because Nick annoyed the hell out of them.
Sentiment: Strong Buy
No, not at all, and that is the problem. Go to clinicaltrialsDOTgov and search for "aldoxorubicin". Scroll down to "Phase 3 Study to Treat Patients With Soft Tissue Sarcomas". It's amazing how much the information freely available on the web differs from FurStain#$%$ piece.